



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2024-25/137

December 10, 2024

To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON	To, The Compliance Officer Syngene International Ltd. Biocon SEZ, Biocon Park, Plot. No. 2 & 3, Bommasandra Indst. Area IV Phase, Jigani Link Rd, Bommasandra Bangalore – 560 099 Karnataka, India
---	---	---

Dear Sir/Madam,

Subject: Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Pursuant to Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, we wish to inform you that Biocon Limited ("the Promoter") has sold 80,00,000 (Eighty Lacs) equity shares of Syngene International Limited (Syngene), subsidiary of the Company, in open market through block deal mechanism resulting in decrease in the shareholding of Syngene by 1.99 % of total holdings on December 10, 2024, as per details as under:

Sl. No	Seller	No. of Shares Held prior to disposal	No. of Shares Sold	% of Sale	Date of Sale
1	Biocon Limited	21,91,85,608	80,00,000	1.99 %	December 10, 2024

Post this transaction, the shareholding of the Company in Syngene shall stand at 52.46%.

Please find enclosed the form in respect of the said disclosure.

We request you to kindly take this to your record.

Thanking You,

Yours faithfully

For **Biocon Limited**

Mayank Verma
Company Secretary & Compliance Officer
Membership No. A18776

Encl: As above

Disclosures under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1.	Name of the Target Company (TC)	Syngene International Limited		
2.	Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Promoter(s) 1. Biocon Limited Promoter Group 2. Biocon Research Limited* 3. Biocon Limited Employee Welfare Trust 4. Ms. Kiran Mazumdar Shaw 5. Mr. Dev Mazumdar 6. Prof. Ravi Rasendra Mazumdar		
3.	Whether the acquirer belongs to Promoter/Promoter group	Promoter (Seller)		
4.	Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
5.	Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share/voting capital of the TC (**)
	Before the acquisition / sale under consideration, holding of:			
	a) Shares carrying voting rights [@]	21,91,85,608	54.45%	54.45%
	b) Shares in the nature of encumbrance (pledge/lien/ non-disposal undertaking/ others)	NIL	NIL	NIL
	c) Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
	d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	NIL	NIL	NIL
	e) Total (a+b+c+d)	21,91,85,608	54.45%	54.45%
	Details of acquisition / sale			
	a) Shares carrying voting rights acquired/sold	80,00,000	1.99%	1.99%
	b) VRs acquired /sold otherwise than by shares	NIL	NIL	NIL
	c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	NIL	NIL	NIL
	d) Shares encumbered / invoked/ released by the acquirer	NIL	NIL	NIL
	e) Total (a+b+c+d)	80,00,000	1.99%	1.99%

After the acquisition / sale, holding of:				
	a) Shares carrying voting rights [@]	21,11,85,608	52.46%	52.46%
	b) Shares encumbered with the acquirer	NIL	NIL	NIL
	c) VRs otherwise than by shares	NIL	NIL	NIL
	d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	NIL	NIL	NIL
	e) Total (a+b+c+d)	21,11,85,608	52.46%	52.46%
6.	Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc.)	Open Market (through block deal mechanism)		
7.	Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	December 10, 2024		
8.	Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 4,02,53,69,810		
9.	Equity share capital / total voting capital of the TC after the said acquisition / sale	Rs. 4,02,53,69,810		
10.	Total diluted share/ voting capital of the TC after the said sale	Rs. 4,02,53,69,810		

*Biocon Research Limited merged with Biocon Biologics India Limited vide order dated February 4, 2020 by the Bengaluru Bench of National Company Law Tribunal ("NCLT").

[@]Reflects shareholding of Biocon Limited only.

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Regulation 31 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Thanking You,

Yours faithfully

For **Biocon Limited**

Mayank Verma
Company Secretary & Compliance Officer
Membership No. A18776